prohibition partners
prohibition partners · page 3
- Events
Business of Cannabis: New York 2025 – Key Takeaways
Business of Cannabis: New York 2025 arrived at a crucial moment not just for the local cannabis industry, but for the entire state.
- Industry Trends
Why is No One Talking About Germany’s Oversupply Problem?
Germany’s telemedicine-fuelled expansion has driven the value of its medical cannabis market up by hundreds of millions of euros in just less than two years.
- Prescribers & Clinics
High-THC Leads Growth as Australia Tightens TGA Prescribing Rules
The medical cannabis industries in Australia and New Zealand are continuing to evolve rapidly, with both markets showing signs of maturation, regulatory recalibration, and expanding export ambitions, according to new data.
- US & Canada
Countdown to Business of Cannabis: New York 2025, Celebrating Our Pioneering Sponsors
Next Thursday, 6 November 2025, Business of Cannabis: New York returns to The Wythe Hotel, Williamsburg, uniting more than 300 leaders from across the cannabis ecosystem for a day of strategic dialogue, networking, and market insight.
- Press releases
Why You Should Attend Business of Cannabis: New York
Industry leaders, regulators and investors meet at Business of Cannabis New York to discuss funding, regulation and sustainable market growth.
- Uncategorized
What’s On the Agenda for Business of Cannabis: New York 2025?
Industry leaders, regulators and investors meet at Business of Cannabis New York to discuss funding, regulation and sustainable market growth.
- Uncategorized
Business of Cannabis: New York 2025 – Policy, Investment and Market Growth
At a Glance Date: Thursday, 6 November 2025 Venue: The Wythe Hotel, Williamsburg, New York Attendees: 200+ industry leaders, investors, and policymakers Focus: Regulation, retail strategy, investment, and market growth Tickets: [Purchase here] Where New York’s Cannabis Industry Connects Business of Cannabis: New York returns to The Wythe Hotel on 6 November 2025, bringing together…
- UK & Europe
What Does the First Official Data on Germany’s Cannabis Reforms Show?
Germany’s booming cannabis market, which Prohibition Partners now estimates to be worth around €670m, is entering uncertain and potentially treacherous territory.
- Opinion
Cultivating Precision: Medocann’s Vision for Ultra-Premium Craft Cannabis on the Global Stage
In today’s crowded cannabis landscape, where “premium” is often used as a buzzword, The Medocann Group is setting a higher bar.
- Uncategorized
‘GMP Is the Foundation of Trust in Our Industry’ – Inside Linnea’s Take on Pharma-Grade Cannabinoids
In the first of a series of interviews focused on the expert contributors to Prohibition Partners’ newly launched Insights Hub, we sat down with Linnea to discuss the increasing importance of GMP certification and pharmaceutical discipline in a rapidly growing cannabis market.
- Medical Cannabis
Why France’s Strict Medical Cannabis Plans Could be its Secret Weapon
Augur Associates and Newsweed, two organisations at the forefront of the ongoing developments in the region, believe that the incoming system not only sidesteps many of the issues other countries have faced in the implementation phase, but that it could reestablish the country’s standing as a model of inspiration for neighbouring states and prospective forthcoming EU supra-regulation.
- Uncategorized
Prohibition Partners Unveils Next-Gen Platform for Tracking European Cannabis Trends
As Europe’s medical cannabis markets grow increasingly interconnected, Prohibition Partners has launched a first-of-its-kind digital knowledge hub to offer real-time insight into production, consumption and cross-border flows.
